Blood test may predict sepsis danger

NCT ID NCT06446947

Recruiting now Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find epigenetic markers in the blood that could predict whether a patient with sepsis will develop the more dangerous septic shock. Researchers will take blood samples from 25 male patients after major digestive cancer surgery who develop sepsis. By comparing markers between those who worsen and those who don't, they hope to identify early warning signs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which sepsis patients are at risk of worsening to septic shock, allowing earlier and more targeted treatment.
What could go wrong: This is a very small, early-stage study with only 25 male patients after specific surgeries, so results may not apply to all sepsis patients and may not lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis Systemic Inflammatory Response Syndrome toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS SEPSIS SYNDROME SEPTIC SHOCK

Contacts and locations

Locations

Service Anesthésie Réanimation - Hôpital Nord - Assistance Publique Hôpitaux de Marseille
RECRUITING

Marseille, Bouches du Rhône, 13015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.